 | • レポートコード：MRC2Q12-16809 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、106ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療 |
| Single User | ￥735,000 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,470,000 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、非小細胞肺がん治療（NSCLC）のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 非小細胞肺がん治療（NSCLC）のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 非小細胞肺がん治療（NSCLC）の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 非小細胞肺がん治療（NSCLC）のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの非小細胞肺がん治療（NSCLC）の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の非小細胞肺がん治療（NSCLC）の売上および2028年までの予測に焦点を当てています。 非小細胞肺がん治療（NSCLC）のグローバル主要企業には、AbbVie Inc.、Astellas Pharma、AstraZeneca、Avid Bioservices Inc.、Bayer Healthcare、Biogen Inc.、Blueprint Medicines Corp、Eli Lilly and Company、Merck & co Inc.、Novartis、Pfizer Inc.などがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 非小細胞肺がん治療（NSCLC）市場は、タイプとアプリケーションによって区分されます。世界の非小細胞肺がん治療（NSCLC）市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 血管新生阻害剤、上皮成長因子受容体遮断剤、キナーゼ阻害剤、微小管安定剤、葉酸代謝拮抗剤、その他 【アプリケーション別セグメント】 腺癌、扁平上皮癌、大細胞癌 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 非小細胞肺がん治療（NSCLC）製品概要 - タイプ別市場（血管新生阻害剤、上皮成長因子受容体遮断剤、キナーゼ阻害剤、微小管安定剤、葉酸代謝拮抗剤、その他） - アプリケーション別市場（腺癌、扁平上皮癌、大細胞癌） - 調査の目的 ・エグゼクティブサマリー - 世界の非小細胞肺がん治療（NSCLC）販売量予測2017-2028 - 世界の非小細胞肺がん治療（NSCLC）売上予測2017-2028 - 非小細胞肺がん治療（NSCLC）の地域別販売量 - 非小細胞肺がん治療（NSCLC）の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別非小細胞肺がん治療（NSCLC）販売量 - 主要メーカー別非小細胞肺がん治療（NSCLC）売上 - 主要メーカー別非小細胞肺がん治療（NSCLC）価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（血管新生阻害剤、上皮成長因子受容体遮断剤、キナーゼ阻害剤、微小管安定剤、葉酸代謝拮抗剤、その他） - 非小細胞肺がん治療（NSCLC）のタイプ別販売量 - 非小細胞肺がん治療（NSCLC）のタイプ別売上 - 非小細胞肺がん治療（NSCLC）のタイプ別価格 ・アプリケーション別市場規模（腺癌、扁平上皮癌、大細胞癌） - 非小細胞肺がん治療（NSCLC）のアプリケーション別販売量 - 非小細胞肺がん治療（NSCLC）のアプリケーション別売上 - 非小細胞肺がん治療（NSCLC）のアプリケーション別価格 ・北米市場 - 北米の非小細胞肺がん治療（NSCLC）市場規模（タイプ別、アプリケーション別） - 主要国別の非小細胞肺がん治療（NSCLC）市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの非小細胞肺がん治療（NSCLC）市場規模（タイプ別、アプリケーション別） - 主要国別の非小細胞肺がん治療（NSCLC）市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の非小細胞肺がん治療（NSCLC）市場規模（タイプ別、アプリケーション別） - 主要国別の非小細胞肺がん治療（NSCLC）市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の非小細胞肺がん治療（NSCLC）市場規模（タイプ別、アプリケーション別） - 主要国別の非小細胞肺がん治療（NSCLC）市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの非小細胞肺がん治療（NSCLC）市場規模（タイプ別、アプリケーション別） - 主要国別の非小細胞肺がん治療（NSCLC）市場規模（トルコ、サウジアラビア） ・企業情報 AbbVie Inc.、Astellas Pharma、AstraZeneca、Avid Bioservices Inc.、Bayer Healthcare、Biogen Inc.、Blueprint Medicines Corp、Eli Lilly and Company、Merck & co Inc.、Novartis、Pfizer Inc. ・産業チェーン及び販売チャネル分析 - 非小細胞肺がん治療（NSCLC）の産業チェーン分析 - 非小細胞肺がん治療（NSCLC）の原材料 - 非小細胞肺がん治療（NSCLC）の生産プロセス - 非小細胞肺がん治療（NSCLC）の販売及びマーケティング - 非小細胞肺がん治療（NSCLC）の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 非小細胞肺がん治療（NSCLC）の産業動向 - 非小細胞肺がん治療（NSCLC）のマーケットドライバー - 非小細胞肺がん治療（NSCLC）の課題 - 非小細胞肺がん治療（NSCLC）の阻害要因 ・主な調査結果 |
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Non-Small Cell Lung Cancer Treatment (NSCLC) estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Non-Small Cell Lung Cancer Treatment (NSCLC) is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Non-Small Cell Lung Cancer Treatment (NSCLC) is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Non-Small Cell Lung Cancer Treatment (NSCLC) is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Non-Small Cell Lung Cancer Treatment (NSCLC) include AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company and Merck & co Inc., etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Non-Small Cell Lung Cancer Treatment (NSCLC) companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Non-Small Cell Lung Cancer Treatment (NSCLC) market. Further, it explains the major drivers and regional dynamics of the global Non-Small Cell Lung Cancer Treatment (NSCLC) market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
AbbVie Inc.
Astellas Pharma
AstraZeneca
Avid Bioservices Inc.
Bayer Healthcare
Biogen Inc.
Blueprint Medicines Corp
Eli Lilly and Company
Merck & co Inc.
Novartis
Pfizer Inc.
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by type and by application segments based on value for the period 2017-2028.
Non-Small Cell Lung Cancer Treatment (NSCLC) Segment by Type
Angiogenesis Inhibitor
Epidermal Growth Factor Receptor Blocker
Kinase Inhibitor
Microtubule Stabilizer
Folate Antimetabolites
Others
Non-Small Cell Lung Cancer Treatment (NSCLC) Segment by Application
Adenocarcinoma
Squamous Cell Carcinoma
Large Cell Carcinoma
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Non-Small Cell Lung Cancer Treatment (NSCLC) market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Non-Small Cell Lung Cancer Treatment (NSCLC) market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Non-Small Cell Lung Cancer Treatment (NSCLC), also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Non-Small Cell Lung Cancer Treatment (NSCLC), and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non-Small Cell Lung Cancer Treatment (NSCLC) revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Non-Small Cell Lung Cancer Treatment (NSCLC) market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Non-Small Cell Lung Cancer Treatment (NSCLC) revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including AbbVie Inc., Astellas Pharma, AstraZeneca, Avid Bioservices Inc., Bayer Healthcare, Biogen Inc., Blueprint Medicines Corp, Eli Lilly and Company and Merck & co Inc., etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Non-Small Cell Lung Cancer Treatment (NSCLC) in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Small Cell Lung Cancer Treatment (NSCLC) companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-Small Cell Lung Cancer Treatment (NSCLC) revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions
1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Angiogenesis Inhibitor
1.2.3 Epidermal Growth Factor Receptor Blocker
1.2.4 Kinase Inhibitor
1.2.5 Microtubule Stabilizer
1.2.6 Folate Antimetabolites
1.2.7 Others
1.3 Market by Application
1.3.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Adenocarcinoma
1.3.3 Squamous Cell Carcinoma
1.3.4 Large Cell Carcinoma
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Perspective (2017-2028)
2.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Growth Trends by Region
2.2.1 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Region (2017-2022)
2.2.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Region (2023-2028)
2.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Dynamics
2.3.1 Non-Small Cell Lung Cancer Treatment (NSCLC) Industry Trends
2.3.2 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Drivers
2.3.3 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Challenges
2.3.4 Non-Small Cell Lung Cancer Treatment (NSCLC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Revenue
3.1.1 Global Top Non-Small Cell Lung Cancer Treatment (NSCLC) Players by Revenue (2017-2022)
3.1.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue Market Share by Players (2017-2022)
3.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue
3.4 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Concentration Ratio
3.4.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Small Cell Lung Cancer Treatment (NSCLC) Revenue in 2021
3.5 Non-Small Cell Lung Cancer Treatment (NSCLC) Key Players Head office and Area Served
3.6 Key Players Non-Small Cell Lung Cancer Treatment (NSCLC) Product Solution and Service
3.7 Date of Enter into Non-Small Cell Lung Cancer Treatment (NSCLC) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Small Cell Lung Cancer Treatment (NSCLC) Breakdown Data by Type
4.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Type (2017-2022)
4.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Type (2023-2028)
5 Non-Small Cell Lung Cancer Treatment (NSCLC) Breakdown Data by Application
5.1 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Historic Market Size by Application (2017-2022)
5.2 Global Non-Small Cell Lung Cancer Treatment (NSCLC) Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2017-2028)
6.2 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type
6.2.1 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2017-2022)
6.2.2 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2023-2028)
6.2.3 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type (2017-2028)
6.3 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application
6.3.1 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2017-2022)
6.3.2 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2023-2028)
6.3.3 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Application (2017-2028)
6.4 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country
6.4.1 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2017-2022)
6.4.2 North America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2017-2028)
7.2 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type
7.2.1 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2017-2022)
7.2.2 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2023-2028)
7.2.3 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type (2017-2028)
7.3 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application
7.3.1 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2017-2022)
7.3.2 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2023-2028)
7.3.3 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Application (2017-2028)
7.4 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country
7.4.1 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2017-2022)
7.4.2 Europe Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2017-2028)
8.2 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type
8.2.1 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2017-2022)
8.2.2 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2023-2028)
8.2.3 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type (2017-2028)
8.3 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application
8.3.1 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Application (2017-2028)
8.4 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region
8.4.1 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2017-2028)
9.2 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type
9.2.1 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2017-2022)
9.2.2 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2023-2028)
9.2.3 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type (2017-2028)
9.3 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application
9.3.1 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2017-2022)
9.3.2 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2023-2028)
9.3.3 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Application (2017-2028)
9.4 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country
9.4.1 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2017-2022)
9.4.2 Latin America Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size (2017-2028)
10.2 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type
10.2.1 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2017-2022)
10.2.2 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Type (2023-2028)
10.2.3 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Type (2017-2028)
10.3 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application
10.3.1 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Share by Application (2017-2028)
10.4 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country
10.4.1 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Non-Small Cell Lung Cancer Treatment (NSCLC) Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 AbbVie Inc.
11.1.1 AbbVie Inc. Company Details
11.1.2 AbbVie Inc. Business Overview
11.1.3 AbbVie Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.1.4 AbbVie Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.1.5 AbbVie Inc. Recent Developments
11.2 Astellas Pharma
11.2.1 Astellas Pharma Company Details
11.2.2 Astellas Pharma Business Overview
11.2.3 Astellas Pharma Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.2.4 Astellas Pharma Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.2.5 Astellas Pharma Recent Developments
11.3 AstraZeneca
11.3.1 AstraZeneca Company Details
11.3.2 AstraZeneca Business Overview
11.3.3 AstraZeneca Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.3.4 AstraZeneca Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.3.5 AstraZeneca Recent Developments
11.4 Avid Bioservices Inc.
11.4.1 Avid Bioservices Inc. Company Details
11.4.2 Avid Bioservices Inc. Business Overview
11.4.3 Avid Bioservices Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.4.4 Avid Bioservices Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.4.5 Avid Bioservices Inc. Recent Developments
11.5 Bayer Healthcare
11.5.1 Bayer Healthcare Company Details
11.5.2 Bayer Healthcare Business Overview
11.5.3 Bayer Healthcare Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.5.4 Bayer Healthcare Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.5.5 Bayer Healthcare Recent Developments
11.6 Biogen Inc.
11.6.1 Biogen Inc. Company Details
11.6.2 Biogen Inc. Business Overview
11.6.3 Biogen Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.6.4 Biogen Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.6.5 Biogen Inc. Recent Developments
11.7 Blueprint Medicines Corp
11.7.1 Blueprint Medicines Corp Company Details
11.7.2 Blueprint Medicines Corp Business Overview
11.7.3 Blueprint Medicines Corp Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.7.4 Blueprint Medicines Corp Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.7.5 Blueprint Medicines Corp Recent Developments
11.8 Eli Lilly and Company
11.8.1 Eli Lilly and Company Company Details
11.8.2 Eli Lilly and Company Business Overview
11.8.3 Eli Lilly and Company Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.8.4 Eli Lilly and Company Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.8.5 Eli Lilly and Company Recent Developments
11.9 Merck & co Inc.
11.9.1 Merck & co Inc. Company Details
11.9.2 Merck & co Inc. Business Overview
11.9.3 Merck & co Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.9.4 Merck & co Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.9.5 Merck & co Inc. Recent Developments
11.10 Novartis
11.10.1 Novartis Company Details
11.10.2 Novartis Business Overview
11.10.3 Novartis Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.10.4 Novartis Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.10.5 Novartis Recent Developments
11.11 Pfizer Inc.
11.11.1 Pfizer Inc. Company Details
11.11.2 Pfizer Inc. Business Overview
11.11.3 Pfizer Inc. Non-Small Cell Lung Cancer Treatment (NSCLC) Introduction
11.11.4 Pfizer Inc. Revenue in Non-Small Cell Lung Cancer Treatment (NSCLC) Business (2017-2022)
11.11.5 Pfizer Inc. Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer